KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Total Current Liabilities (2016 - 2025)

AbbVie (ABBV) has disclosed Total Current Liabilities for 14 consecutive years, with $43.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 11.72% to $43.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $43.3 billion, a 11.72% increase, with the full-year FY2025 number at $43.3 billion, up 11.72% from a year prior.
  • Total Current Liabilities was $43.3 billion for Q4 2025 at AbbVie, up from $39.4 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $43.3 billion in Q4 2025 to a low of $27.6 billion in Q1 2023.
  • A 5-year average of $35.5 billion and a median of $35.0 billion in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 93.98% in 2021, then dropped 16.07% in 2022.
  • AbbVie's Total Current Liabilities stood at $35.2 billion in 2021, then decreased by 16.07% to $29.5 billion in 2022, then rose by 28.11% to $37.8 billion in 2023, then increased by 2.4% to $38.7 billion in 2024, then increased by 11.72% to $43.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Total Current Liabilities are $43.3 billion (Q4 2025), $39.4 billion (Q3 2025), and $39.8 billion (Q2 2025).